Kuldev Singh, MD, PhD
•
1 j'aime•501 vues
Kuldev Singh, MD, PhD "Spotlight on Pressure Reduction: Market Overview" Presentation from OIS@ASCRS 2015
Recommandé
Contenu connexe
Tendances
Tendances (20)
En vedette
En vedette (20)
Similaire à Kuldev Singh, MD, PhD
Similaire à Kuldev Singh, MD, PhD (20)
Plus de Healthegy
Plus de Healthegy (20)
Dernier
Dernier (20)
Kuldev Singh, MD, PhD
- 1. Spotlight on Pressure Reduction: Market Overview Kuldev Singh, M.D., M.P.H. Professor of Ophthalmology Director, Glaucoma Service Stanford University
- 2. Glaucoma Patients by Region 0 20 40 60 80 100 120 140 160 2015 2020 NumberofGlaucomaPatients(millions) Rest of World Latin America India China Other Wealthy Nations Japan Western Europe United States Courtesy of Dave Harmon Market Scope
- 3. Glaucoma by Disease Category Open Angle 42% Closed Angle 15% Secondary 7% Ocular Hypertension 36% 125 Million Courtesy of Dave Harmon Market Scope
- 4. Courtesy of Dr. Cynthia Mattox
- 5. Glaucoma Prevalence by Age Prevent Blindness America Future of Vision Report 2014 Courtesy of Dr. Cynthia Mattox
- 6. Glaucoma: The Big Picture 25-50% aware that they have disease* Those aware are often not under care Those under care are often non compliant Unpredictable natural history of disease Small percentage go blind Lowering IOP reduces but does not eliminate risk *Sommer A, et al. Arch Ophthalmol. 1991;109:1990-95.
- 7. U.S. Ophthalmologists Specialty 41% Courtesy of Dr. Gregory Skuta and AAO Member Services Comprehensive with Specialty 19% Comprehensive 40%
- 8. U.S. Specialty Breakdown Retina/Vitreous 29% Cornea and External Disease 18% Pediatrics and Strabismus 14% Oculoplastics and Orbit 12% Cataract/Anterior Segment 8% Other 3% Neuro 2% Refractive Surgery 1% Uveitis 1% Glaucoma 12% Courtesy of Dr. Gregory Skuta and AAO Member Services
- 9. Global Glaucoma Pharmaceutical Market Revenues by Category Branded Prostaglandin 28% Generic Prostaglandin 7% Beta Blockers… Carbonic Anhydrase Inhibitors 11% Alpha Agonists 11% Fixed Combo Drugs 37% Other 2% $4.7 Billion in 2015 Courtesy of Dave Harmon Market Scope
- 11. Surgical Trends: 1994-2012 0 20000 40000 60000 80000 100000 120000 140000 160000 180000 200000 Trabec Tube CPC LTP LPI Courtesy of Drs. William Rich, Michael Repka and Gregory Skuta
- 12. 0 50 100 150 200 250 300 2013 2014 2019 (Forecast) 64 64 62 44 46 54 20 42 255 USGlaucomaSurgeries(000) Filtration Tube Shunts MIGS U.S. Glaucoma Surgical Procedures Courtesy of Dave Harmon Market Scope
- 13. Spotlight on Pressure Reduction: Addressing Unmet Needs in Glaucoma Care More effective first line and adjunctive medications Glaucoma operation safer than trabeculectomy Novel drug delivery to improve compliance
- 14. SPOTLIGHT ON PRESSURE REDUCTION Company Presentations